Thanks for your analysis, but you are not an oncologist 😶
It sounds like you prefer placebo trials…
The ongoing UCLA trial supported by continuing peer-reviewed grants from the U.S. NIH, and the Roswell research supported by a peer-reviewed grant from the U.S. DoD are combo trials and they are also randomized controlled trials (with placebo groups).
These PII studies are investigating DC technologies in combo with PD1 blockade technology (NWBO owns the commercial rights to both novel DC technologies). Hiltonol is also a notable combo agent and a PII study that began years ago recently concluded.
Rather than listening to random baseless nonsense, we want to hear what the clinical data say, what independent peer-reviewers say about those data, and what government regulators have to say.
Market Data 
Markets 
AI
